We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are ...

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where Immunitybio, Inc. (NASDAQ:IBRX) stands against other firms that took a hit on ...

Fintel reports that on January 10, 2025, BTIG initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation.

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

We recently compiled a list of the 10 Firms Shine Amid Wall Street’s Lackluster Trading. In this article, we are going to ...

ImmunityBio (IBRX) stock was up 15% Thursday, the day after it issued updates on its regulatory submissions in the United ...

ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...

ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low ...

In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other top small cap stocks to buy with the highest upside potential. On December 30 ...

The firm decreased its portfolio allocation in IBRX by 24.70% over the last quarter. XBI - SPDR(R) S&P(R) Biotech ETF holds 5,238K shares representing 0.75% ownership of the company. In its prior ...

ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a ...